[ad_1]
Prescgere magazine unveiled on Thursday its new list of a hundred “more dangerous than useful” drugs, to be avoided because of the “disproportionate” health risks they pose to patients, against newcomers like Propecia male pattern baldness.
Among those added to this blacklist this year are two drugs they expose “disproportionate” negative effects in relation to their low efficacy or the benignity of the disorders treated. This is the case of the famous drug for moderate hair loss in men, “finasteride 1 mg” (Propecia and generics).
The ANSM Medicines Agency has already warned about the risks of psychiatric (anxiety, depression) and sexual disorders (including ejaculation disorders and decreased libido) that should lead to the suspension of this anti-baldness treatment.
Also pinned: piracetam (Nootropyl and generics), a “vasodilator” licensed in various indications including dizziness, and as an adjunct treatment for chronic minor (cognitive or sensorineural) disorders related to aging.
93 sold in France
Three other drugs are reported, which have some effectiveness, but with disproportionate adverse effects or for which there are other less dangerous options.
It is esketamine (Spravato) nasal spray “of uncertain efficacy” against depression resistant to antidepressants; pimecrolimus (Elidel not marketed in France) against atopic eczema, but with an increased risk of skin cancer and lymphoma. The third is romosozumab (Evenity, not marketed in France) for severe osteoporosis in postmenopausal women.
About ten drugs from the gliflozin family, against diabetes, they are also among the drugs to avoid.
Sore throat, cough, cold … other products not recommended in previous years are still high on the list.
The 2021 list covers 112 drugs, 93 of which are marketed in France, explains Prescgere. The drugs referenced in this list are “causes of death, hospitalization, or serious or very troublesome adverse effects, largely preventable,” the magazine states. However, “they are not necessarily future ‘Mediators’, at the center of scandals and trials (…). Especially if all health professionals react in time”, he stresses.
This report is available on the journal’s website (https://www.prescellare.org/ecarter).
Source link
